Anokion Announces Exclusive Strategic Collaboration with Celgene to Develop Novel Tolerance-Inducing Therapeutics for Autoimmune Diseases

Anokion Announces Exclusive Strategic Collaboration with Celgene to Develop Novel Tolerance-Inducing Therapeutics for Autoimmune Diseases

Date
January 9, 2017

LAUSANNE, Switzerland, and CAMBRIDGE, MA January 9, 2017

Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the formation of an exclusive global research collaboration with Celgene Switzerland LLC, an affiliate of Celgene Corp.

Read the full news release from Anokion